title: Immunogenicity of HLA-DR1 Restricted Peptides Derived from Leishmania major gp63 Using FVB/N-DR1 Transgenic Mouse Model.
abstract: BACKGROUND
  Leishmaniasis is a worldwide disease prevalent in tropical and sub-tropical countries. In the present study the immunogenicity of three human HLA-DR1 restricted peptides derived from L. major gp63 protein was evaluated using FVB/N-DR1 transgenic mouse model.
  
  
  METHODS
  The immunity generated by three MHC class II - restricted peptides with the sequence of AARLVRLAAAGAAVT (AAR), AAPLVRLAAAGAAVT (AAP) and SRYDQLVTRVVTHE (ASR) derived from L. major gp63 protein were predicted using a web-based software (SYFPEITHI) and tested in FVB/N-DR1 transgenic mice.
  
  
  RESULTS
  Immunization of FVB/N-DR1 transgenic mice with one of the three predicted peptides (AAR) resulted in high levels of Th1-type immune response as well as significant levels of IFN-γ detected by Proliferation assay and ELISA.
  
  
  CONCLUSIONS
  The results indicate a high level of immunogenicity for AAR, which can be a potent candidate for peptide vaccine in Leishmania infections.
authors.affiliation: Dept. of Laboratory Science, School of Paraveterinary Sciences, Bu-Ali Sina University, Hamadan, Iran.
authors.forename: H
authors.initials: H
authors.lastname: Rezvan
keywords: FVB/N-DR1 transgenic mice; IFN-γ; Leishmania major; Peptide; Proliferation; gp63
references.citation: Eur J Immunol. 1994 Dec;24(12):3038-43
references.pmid: 7805731
references.citation: Iran J Parasitol. 2011 Dec;6(4):60-75
references.pmid: 22347315
references.citation: Vaccine. 2004 Sep 28;22(29-30):4097-100
references.pmid: 15364462
references.citation: Vaccine. 1999 Mar 17;17(11-12):1298-300
references.pmid: 10195763
references.citation: Vaccine. 1998 Aug-Sep;16(14-15):1415-9
references.pmid: 9711781
references.citation: Arch Pathol Lab Med. 2002 Apr;126(4):471-3
references.pmid: 11900576
references.citation: J Biomol Struct Dyn. 2006 Oct;24(2):109-21
references.pmid: 16928134
references.citation: Parasite Immunol. 1999 Sep;21(9):461-73
references.pmid: 10476055
references.citation: Health Policy Plan. 1999 Mar;14(1):70-6
references.pmid: 10351471
references.citation: Exp Hematol. 2006 Apr;34(4):486-96
references.pmid: 16569595
references.citation: J Immunol. 2004 Jun 1;172(11):6783-9
references.pmid: 15153496
references.citation: Eur J Immunol. 1999 Oct;29(10):3112-21
references.pmid: 10540322
references.citation: Vaccine. 2003 Jan 30;21(7-8):593-5
references.pmid: 12531323
references.citation: J Exp Med. 1992 Dec 1;176(6):1693-702
references.pmid: 1460426
references.citation: Vaccine. 2007 May 30;25(22):4437-46
references.pmid: 17442465
references.citation: Comp Immunol Microbiol Infect Dis. 2004 Sep;27(5):305-18
references.pmid: 15225981
references.citation: Immunogenetics. 1999 Nov;50(3-4):213-9
references.pmid: 10602881
references.citation: Vaccine. 2004 Apr 16;22(13-14):1728-31
references.pmid: 15068856
references.citation: Crit Rev Microbiol. 1995;21(2):123-52
references.pmid: 7639932
references.citation: Cancer Immunol Immunother. 2005 Mar;54(3):243-53
references.pmid: 15449037
references.citation: Infect Immun. 1996 Dec;64(12):5129-37
references.pmid: 8945556
references.citation: Parasite Immunol. 2009 Jul;31(7):373-83
references.pmid: 19527453
references.citation: Exp Parasitol. 2003 Mar-Apr;103(3-4):143-51
references.pmid: 12880591